Sort   by:  
 Page size 
ProteomicsLC-MS/MS analyses of human PDAC cell lines after treatment with a new SUMO inhibitor
Pancreatic ductal adenocarcinoma (PDAC) still carries a dismal prognosis with overall five-year survival of 8%. Conventional combination chemotherapies are a clear advance in the treatment of PDAC, however subtypes of the disease exist, which exhibit extensive resistance to such therapies. Genomic M...
ORGANISM(S): Homo sapiens (Human) 
2020-01-06 | PXD011347 | Pride
Pancreatic cancer Myc Sumo Lc-ms/ms 
ProteomicsIdentification of SENP6 target proteins by endogenous SUMO2/3 IP-MS
Cellular signaling by the ubiquitin-related SUMO pathway relies on coordinated conjugation and deconjugation events. SUMO-specific deconjugating enzymes counterbalance SUMOylation, but comprehensive insight into their substrate specificity and regulation is missing. By characterizing SENP6 we define...
ORGANISM(S): Homo sapiens (Human) 
2019-11-20 | PXD015134 | Pride
Sumo Human Senp Lc-ms/ms 
Sort   by:  
 Page size